Response

Chest

Volumn 144, Issue 4, 2013, Pages 1418-1419

  Durmowicz, Anthony G ^a   Witzmann, Kimberly A ^a   Rosebraugh, Curtis J ^a   Chowdhury, Badrul A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885159633     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1517     Document Type: Letter

References (3)

1. Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest. 2013; 143 (1): 14-18.
2. Draft Guidance for Industry: Qualification Process for Drug Development Tools. Silver Spring, MD: US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2010.
3. Quinton P, Molyneux L, Ip W, et al. b -Adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med. 2012; 186 (8): 732-739.